
    
      This retrospective, open-label, post-market study evaluates the safety and efficacy of
      Transoral Incisionless Fundoplication (TIF) performed with EsophyX (brand name) in a broad
      range of GastroEsophageal Reflux Disease (GERD) patients treated at high volume centers
      across the United States, in clinical routine practice, as standard of care.
    
  